Skip to main content
SpringerLink
Log in

Quetiapine ER vs aripiprazole in youths: cardiometabolic effects

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Tolerability and Efficacy of Antipsychotics; NCT01119014; EudraCT 2009−016715−38

Reference

  • Jensen KG, et al. Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial. Journal of the American Academy of Child and Adolescent Psychiatry : 8 Mar 2019. Available from: URL: http://doi.org/10.1016/j.jaac.2019.01.015

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Quetiapine ER vs aripiprazole in youths: cardiometabolic effects. Reactions Weekly 1746, 11 (2019). https://doi.org/10.1007/s40278-019-59449-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-59449-7

Search

Navigation